Viral-based gene delivery and regulated gene expression for targeted cancer therapy
Authors:
- 30 November 2009
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Drug Delivery
- Vol. 7 (1) , 19-35
Abstract
Importance of the field: Cancer is both a major health concern and a care-cost issue in the US and the rest of the world. It is estimated that there will be a total of 1,479,350 new cancer cases and 562,340 cancer deaths in 2009 within the US alone. One of the major obstacles in cancer therapy is the ability to target specifically cancer cells. Most existing chemotherapies and other routine therapies (such as radiation therapy and hormonal manipulation) use indiscriminate approaches in which both cancer cells and non-cancerous surrounding cells are treated equally by the toxic treatment. As a result, either the cancer cell escapes the toxic dosage necessary for cell death and consequently resumes replication, or an adequate lethal dose that kills the cancer cell also causes the cancer patient to perish. Owing to this dilemma, cancer- or organ/tissue-specific targeting is greatly desired for effective cancer treatment and the reduction of side effect cytotoxicity within the patient.Areas covered in this re...Keywords
This publication has 115 references indexed in Scilit:
- Construction of an MUC-1 promoter driven, conditionally replicating adenovirus that expresses the sodium iodide symporter for gene therapy of breast cancerBreast Cancer Research, 2009
- In Vivo Retargeting of Adenovirus Type 5 to αvβ6 Integrin Results in Reduced Hepatotoxicity and Improved Tumor Uptake following Systemic DeliveryJournal of Virology, 2009
- Oncolytic Rat Parvovirus H-1PV, a Candidate for the Treatment of Human Lymphoma: In Vitro and In Vivo StudiesMolecular Therapy, 2009
- Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cellsProceedings of the National Academy of Sciences, 2009
- High Mobility Group Box2 Promoter-controlled Suicide Gene Expression Enables Targeted Glioblastoma TreatmentMolecular Therapy, 2009
- Oncolytic Reovirus Effectively Targets Breast Cancer Stem CellsMolecular Therapy, 2009
- Phase I Clinical Trial of Locoregional Administration of the Oncolytic Adenovirus ONYX-015 in Combination with Mitomycin-C, Doxorubicin, and Cisplatin Chemotherapy in Patients with Advanced Sarcomas2009
- Oncolytic virotherapy for ovarian carcinomatosis using a replication-selective vaccinia virus armed with a yeast cytosine deaminase geneCancer Gene Therapy, 2007
- In vitro evaluation of cancer-specific NF-κB-CEA enhancer–promoter system for 5-fluorouracil prodrug gene therapy in colon cancer cell linesBritish Journal of Cancer, 2007
- Clinical Implications of the p53 Tumor-Suppressor GeneNew England Journal of Medicine, 1993